Physician profile
Rita A Clement
NPI 1508834201
$2,893.93
in general payments reported to CMS, 2019-2025
26 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $554 · 2021: $657 · 2022: $495 · 2023: $206 · 2024: $150 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.76 | 2019-2023 | Liletta |
| Therapeuticsmd, INC. | $372.70 | 2019-2022 | |
| Pfizer INC. | $349.35 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.60 | 2019-2022 | |
| Coopersurgical, INC. | $181.77 | 2019-2023 | Paragard T 380a |
| Agile Therapeutics, INC. | $178.61 | 2021-2024 | Twirla |
| Lupin INC. | $150.76 | 2019-2020 | |
| Allergan, INC. | $137.14 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $122.82 | 2022-2025 | |
| Ethicon US, LLC | $115.00 | 2021 | |
| Exeltis, USA INC. | $108.89 | 2020-2022 | |
| Astellas Pharma US INC | $107.09 | 2024-2025 | Veozah |
| Daiichi Sankyo INC. | $65.34 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $51.71 | 2019 | |
| Exact Sciences Corporation | $47.75 | 2023-2024 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $40.00 | 2019-2025 | Femlyv |
| Evofem Biosciences, INC. | $34.92 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $33.66 | 2020-2022 | |
| Amgen INC. | $32.68 | 2019-2022 | |
| Becton, Dickinson and Company | $20.45 | 2023 | Bd Onclarity |
| Glaxosmithkline, LLC. | $18.47 | 2021 | |
| Merck Sharp & Dohme LLC | $17.03 | 2021 | |
| Myovant Sciences INC. | $16.93 | 2022 | |
| Sumitomo Pharma America, INC. | $16.55 | 2023 | Myfembree |
| Hologic Sales and Service, LLC | $13.50 | 2020 | |
| Duchesnay USA Incorporated | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Clement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.